Cidara Therapeutics Inc. (NASDAQ:CDTX)‘s stock had its “outperform” rating reiterated by research analysts at Wedbush in a report released on Friday. They presently have a $22.00 price objective on the biotechnology company’s stock. Wedbush’s price target would suggest a potential upside of 101.83% from the company’s previous close.

A number of other analysts have also recently commented on CDTX. BTIG Research reiterated a “buy” rating and issued a $24.00 price target on shares of Cidara Therapeutics in a research note on Monday, August 15th. Zacks Investment Research upgraded shares of Cidara Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, August 29th. WBB Securities cut shares of Cidara Therapeutics from a “hold” rating to a “sell” rating and set a $10.50 price target for the company. in a research note on Friday, September 23rd. Cantor Fitzgerald began coverage on shares of Cidara Therapeutics in a research note on Thursday, October 27th. They issued a “buy” rating and a $20.00 price target for the company. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $20.00 price target on shares of Cidara Therapeutics in a research note on Monday, August 15th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company’s stock. Cidara Therapeutics presently has an average rating of “Buy” and an average target price of $18.25.

Analyst Recommendations for Cidara Therapeutics (NASDAQ:CDTX)

Cidara Therapeutics (NASDAQ:CDTX) opened at 10.90 on Friday. The firm has a 50-day moving average of $10.31 and a 200-day moving average of $11.23. The firm’s market capitalization is $151.58 million. Cidara Therapeutics has a 52-week low of $8.65 and a 52-week high of $18.07.

Cidara Therapeutics (NASDAQ:CDTX) last announced its quarterly earnings results on Thursday, August 11th. The biotechnology company reported ($0.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by $0.09. On average, equities research analysts forecast that Cidara Therapeutics will post ($3.31) EPS for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the company. Rhumbline Advisers acquired a new position in Cidara Therapeutics during the second quarter worth approximately $145,000. Teachers Advisors Inc. raised its position in Cidara Therapeutics by 103.0% in the second quarter. Teachers Advisors Inc. now owns 14,066 shares of the biotechnology company’s stock worth $145,000 after buying an additional 7,137 shares in the last quarter. Spark Investment Management LLC raised its position in Cidara Therapeutics by 26.7% in the second quarter. Spark Investment Management LLC now owns 14,700 shares of the biotechnology company’s stock worth $151,000 after buying an additional 3,100 shares in the last quarter. Schwab Charles Investment Management Inc. acquired a new position in Cidara Therapeutics during the second quarter worth approximately $177,000. Finally, Emerald Acquisition Ltd. acquired a new position in Cidara Therapeutics during the second quarter worth approximately $183,000. 49.82% of the stock is currently owned by institutional investors and hedge funds.

Cidara Therapeutics Company Profile

Cidara Therapeutics, Inc, formerly K2 Therapeutics, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections.

5 Day Chart for NASDAQ:CDTX

Receive News & Stock Ratings for Cidara Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics Inc. and related stocks with our FREE daily email newsletter.